| 0.4804 -0.031 (-6.01%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.83  |
1-year : | 1.01 |
| Resists | First : | 0.71 |
Second : | 0.86 |
| Pivot price | 0.6 |
|||
| Supports | First : | 0.45 |
Second : | 0.37 |
| MAs | MA(5) : | 0.52 |
MA(20) : | 0.64 |
| MA(100) : | 1.53 |
MA(250) : | 3.87  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 8.2 |
| RSI | RSI(14): 24 |
|||
| 52-week | High : | 145.46 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PPCB ] has closed above bottom band by 12.0%. Bollinger Bands are 82.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 84 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.52 - 0.52 | 0.52 - 0.53 |
| Low: | 0.45 - 0.45 | 0.45 - 0.45 |
| Close: | 0.47 - 0.48 | 0.48 - 0.48 |
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Wed, 07 Jan 2026
Propanc Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
Thu, 04 Dec 2025
Propanc Biopharma (Nasdaq: PPCB) targets fibrosis, cancer via PRP EMT research - Stock Titan
Mon, 17 Nov 2025
Propanc Biopharma (Nasdaq: PPCB) Raises $4M, Lists on Nasdaq, Sets $100M Facility - Stock Titan
Tue, 04 Nov 2025
Propanc Biopharma, Inc. Announces Strategic Initiative to Acquire Undervalued Digital Asset Treasury Companies - Quiver Quantitative
Thu, 02 Oct 2025
Does Propanc Biopharma (NASDAQ:PPCB) Have A Healthy Balance Sheet? - simplywall.st
Thu, 28 Aug 2025
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - newswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 5.01e+006 (%) |
| Held by Institutions | 62.4 (%) |
| Shares Short | 257 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.166e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -427.3 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 76.64 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 272.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.32 |
| Dividend | 0 |
| Forward Dividend | 236670 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|